Company Profiles

driven by the PitchBook Platform

Axelar

Description

Developer of medicines for the treatment of cancer and other diseases. The company focuses its research and other activities on inhibitors of the insulin-like growth factor-1 (IGF-1) receptor and their applications in important human diseases, especially cancer.

2003

Founded

PRIVATE

Status

1-10

Employees

Later Stage VC

Latest Deal Type

$19.7M

Total Amount Raised

3

Investors

Description

Developer of medicines for the treatment of cancer and other diseases. The company focuses its research and other activities on inhibitors of the insulin-like growth factor-1 (IGF-1) receptor and their applications in important human diseases, especially cancer.

Website:

www.axelar.se

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

Karolinska Institutet Science Park Fogdevreten 2 SE-171 65 SolnaSweden +46 (0)85 24 86 965
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Axelar's full profile, request a free trial.

Axelar Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Axelar Investors (3)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
b-to-v PartnersVenture CapitalMinority000 0000000 0000
ÖstersjöstiftelsenOtherMinority000 0000000 0000
Rosetta Capital(London)Venture CapitalMinority000 0000000 0000
b-to-v Partners Venture Capital
Östersjöstiftelsen Other
Rosetta Capital(London) Venture Capital

Axelar Executive Team (8)

NameTitleBoard
Seat
Contact
Info
Lars Abrahmsén Ph.DVice President, Preclinical Development & Chief Scientific Officer
Maria KlockareDirector, Clinical Operations
Ninus Caram-Lelham Ph.DDirector CMC, Drug Substance
Ann-Sofie SternåsDirector, Intellectual Property
Kristina CarlsonDirector, Regulatory Affairs
Lars Abrahmsén Ph.D Vice President, Preclinical Development & Chief Scientific Officer
Maria Klockare Director, Clinical Operations
Ninus Caram-Lelham Ph.D Director CMC, Drug Substance
Ann-Sofie Sternås Director, Intellectual Property
Kristina Carlson Director, Regulatory Affairs

Axelar Board Members (7)

NameRepresentingRoleSinceContact
Info
Fredrik Gilstring MDAxelarBoard Member000 0000
Goran PetterssonSelfBoard Member000 0000
Jonas Ekblom Ph.DSelfChairman & Business Advisor000 0000
Jonathan Hepple Ph.DRosetta Capital(London)Partner000 0000
Magnus AxelsonAxelarBoard Member & Co-Founder000 0000
Fredrik Gilstring MD Board Member Axelar
Goran Pettersson Board Member Self
Jonas Ekblom Ph.D Chairman & Business Advisor Self
Jonathan Hepple Ph.D Partner Rosetta Capital(London)
Magnus Axelson Board Member & Co-Founder Axelar
Request full access to PitchBook